Display options
Cite
Rasche M, Zimmermann M, Steidel E, et al. Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. Cancers (Basel). 2021;13(10)doi: 10.3390/cancers13102336.
Rasche, M., Zimmermann, M., Steidel, E., Alonzo, T., Aplenc, R., Bourquin, J. P., Boztug, H., Cooper, T., Gamis, A. S., Gerbing, R. B., Janotova, I., Klusmann, J. H., Lehrnbecher, T., Mühlegger, N., Neuhoff, N. V., Niktoreh, N., Sramkova, L., Stary, J., Waack, K., Walter, C., Creutzig, U., Dworzak, M., Kaspers, G., Kolb, E. A., & Reinhardt, D. (2021). Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. Cancers, 13(10), . https://doi.org/10.3390/cancers13102336
Rasche, Mareike, et al. "Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG." Cancers vol. 13,10 (2021). doi: https://doi.org/10.3390/cancers13102336
Rasche M, Zimmermann M, Steidel E, Alonzo T, Aplenc R, Bourquin JP, Boztug H, Cooper T, Gamis AS, Gerbing RB, Janotova I, Klusmann JH, Lehrnbecher T, Mühlegger N, Neuhoff NV, Niktoreh N, Sramkova L, Stary J, Waack K, Walter C, Creutzig U, Dworzak M, Kaspers G, Kolb EA, Reinhardt D. Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. Cancers (Basel). 2021 May 12;13(10). doi: 10.3390/cancers13102336. PMID: 34066095; PMCID: PMC8151466.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 May 12;13(10). doi: 10.3390/cancers13102336.

Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG.

Cancers

Mareike Rasche, Martin Zimmermann, Emma Steidel, Todd Alonzo, Richard Aplenc, Jean-Pierre Bourquin, Heidrun Boztug, Todd Cooper, Alan S Gamis, Robert B Gerbing, Iveta Janotova, Jan-Henning Klusmann, Thomas Lehrnbecher, Nora Mühlegger, Nils V Neuhoff, Naghmeh Niktoreh, Lucie Sramkova, Jan Stary, Katharina Waack, Christiane Walter, Ursula Creutzig, Michael Dworzak, Gertjan Kaspers, Edward Anders Kolb, Dirk Reinhardt

Affiliations

  1. Department of Pediatric Hematology-Oncology, Pediatrics III, University Hospital of Essen, 45147 Essen, Germany.
  2. Department of Pediatric Hematology and Oncology, Hannover Medical School, 30625 Hannover, Germany.
  3. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
  4. Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
  5. Division of Pediatric Hematology/Oncology, University Children's Hospital Zurich, CH-8032 Zurich, Switzerland.
  6. St Anna Children's Hospital and Children's Cancer Research Institute, Department of Pediatrics, Medical University of Vienna, 1090 Vienna, Austria.
  7. Seattle Children's Hospital, Seattle, WA 98105, USA.
  8. Children's Mercy Hospitals and Clinics, Kansas City, MO 64108, USA.
  9. Children's Oncology Group, Monrovia, CA 91016, USA.
  10. Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, 150 06 Prague, Czech Republic.
  11. Clinic for Pediatrics 1, Martin Luther University Halle-Wittenberg, 06108 Halle, Germany.
  12. Division for Pediatric Hematology and Oncology, Hospital for Children and Adolescents, University Hospital, Goethe University Frankfurt am Main, 60590 Frankfurt, Germany.
  13. Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands.
  14. Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, 1105 AZ Amsterdam, The Netherlands.
  15. Nemours/Alfred I. du Pont Hospital for Children, Wilmington, DE 19803, USA.

PMID: 34066095 PMCID: PMC8151466 DOI: 10.3390/cancers13102336

Abstract

Post-relapse therapy remains critical for survival in children with acute myeloid leukemia (AML). We evaluated survival, response and prognostic variables following relapse in independent cooperative group studies conducted by COG and the population-based AML-BFM study group. BFM included 197 patients who relapsed after closure of the last I-BFM relapse trial until 2017, while COG included 852 patients who relapsed on the last Phase 3 trials (AAML0531, AAML1031). Overall survival at 5 years (OS) was 42 ± 4% (BFM) and 35 ± 2% (COG). Initial high-risk features (BFM 32 ± 6%, COG 26 ± 4%) and short time to relapse (BFM 29 ± 4%, COG 25 ± 2%) predicted diminished survival. In the BFM dataset, there was no difference in OS for patients who had a complete remission with full hematopoietic recovery (CR) following post-relapse re-induction compared to those with partial neutrophil and platelet recovery (CRp and CRi) only (52 ± 7% vs. 63 ± 10%,

Keywords: acute myeloid leukemia; childhood acute myeloid leukemia; pediatric; relapse; salvage therapy

References

  1. J Clin Oncol. 2014 Sep 20;32(27):3021-32 - PubMed
  2. Blood Adv. 2020 Dec 22;4(24):6117-6126 - PubMed
  3. Blood. 1996 Jun 15;87(12):4979-89 - PubMed
  4. Leukemia. 2005 Dec;19(12):2130-8 - PubMed
  5. Leukemia. 2010 Aug;24(8):1422-8 - PubMed
  6. J Clin Oncol. 2015 Apr 10;33(11):1258-64 - PubMed
  7. Leukemia. 1999 Jan;13(1):25-31 - PubMed
  8. Cancer. 2007 Jan 1;109(1):157-63 - PubMed
  9. Haematologica. 2020 Jul;105(7):1879-1886 - PubMed
  10. Blood. 2012 Oct 18;120(16):3187-205 - PubMed
  11. J Clin Oncol. 2010 Apr 1;28(10):1766-71 - PubMed
  12. Blood. 2012 Aug 23;120(8):1581-8 - PubMed
  13. J Clin Oncol. 2003 Aug 1;21(15):2940-7 - PubMed
  14. Leukemia. 2005 Dec;19(12):2025-9 - PubMed
  15. Leukemia. 1998 Oct;12(10):1534-8 - PubMed
  16. J Clin Oncol. 2013 Feb 10;31(5):599-607 - PubMed
  17. Haematologica. 2014 Sep;99(9):1472-8 - PubMed
  18. J Clin Oncol. 2003 Dec 15;21(24):4642-9 - PubMed
  19. Blood Rev. 2018 Sep;32(5):416-425 - PubMed
  20. J Clin Oncol. 2003 Dec 1;21(23):4377-85 - PubMed
  21. Leukemia. 2005 Dec;19(12):2030-42 - PubMed
  22. Expert Rev Anticancer Ther. 2021 Jan;21(1):45-52 - PubMed
  23. Blood. 2013 Jul 11;122(2):170-8 - PubMed
  24. Lancet Oncol. 2010 Jun;11(6):543-52 - PubMed
  25. J Clin Oncol. 1990 May;8(5):813-9 - PubMed
  26. Blood Adv. 2020 Oct 27;4(20):5050-5061 - PubMed
  27. Haematologica. 2008 Sep;93(9):1418-20 - PubMed
  28. J Clin Oncol. 2015 Sep 20;33(27):2949-62 - PubMed
  29. Br J Haematol. 2007 Jan;136(2):229-236 - PubMed
  30. Br J Haematol. 2017 Aug;178(4):592-602 - PubMed
  31. Leukemia. 2018 Oct;32(10):2167-2177 - PubMed
  32. Int J Hematol. 2014 Aug;100(2):171-9 - PubMed
  33. J Clin Oncol. 2011 Jan 20;29(3):310-5 - PubMed

Publication Types

Grant support